



- (51) International Patent Classification:
A61K 39/00 (2006.01) A61K 47/48 (2006.01)
A61K 39/395 (2006.01)
- (21) International Application Number:
PCT/US2016/045655
- (22) International Filing Date:
4 August 2016 (04.08.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/200,726 4 August 2015 (04.08.2015) US
- (71) Applicant: DUKE UNIVERSITY [US/US]; 2812 Erwin Road, Suite 306, Durham, NC 27705 (US).
- (72) Inventors: CHILKOTI, Ashutosh; 1001 Gloria Avenue, Durham, NC 27701 (US). BANSKOTA, Samagya; c/o Duke University, P.O. Box 90271, Durham, NC 27708-0281 (US). YOUSEFPOUR, Parisa; c/o Duke University, P.O. Box 90271, Durham, NC 27708-0281 (US). BHAT-TACHARYYA, Jayanta; c/o Duke University, P.O. Box 90271, Durham, NC 27708-0281 (US).
- (74) Agent: COX, Julia, M.; Michael Best & Friedrich LLP, 100 East Wisconsin Avenue, Suite 3300, Milwaukee, WI 53202-4108 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- Published:
- with international search report (Art. 21(3))
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: GENETICALLY ENCODED INTRINSICALLY DISORDERED STEALTH POLYMERS FOR DELIVERY AND METHODS OF USING SAME



FIG. 1A



FIG. 1B




FIG. 1C

(57) Abstract: Provided herein are conjugates including a polypeptide and one or more drug molecules. The polypeptide includes one or more charged motifs, and may further include one or more uncharged motifs. The conjugates may be used to effectively deliver the drug molecule to a subject.



GENETICALLY ENCODED INTRINSICALLY DISORDERED STEALTH POLYMERS FOR DELIVERY AND METHODS OF USING SAME

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 62/200,726, filed August 4, 2015, which is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under grant 5R01EB000188 R01 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD

[0003] The disclosure relates to methods of drug delivery and, more particularly, to zwitterionic polypeptides conjugated to therapeutics. The conjugates have improved biocompatibility and biodegradability. In some embodiments, the conjugates may be recombinantly expressed, and thereby able to be designed with precision and manipulated at the gene level.

INTRODUCTION

[0004] Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short *in vivo* circulation. These challenges in drug delivery lead to decreased therapeutic efficacy and increased risk of off-target toxicity. Attaching macromolecular carriers to drugs can improve their solubility, plasma half-life, tumor-specific uptake, and their overall therapeutic potential. Various materials, mostly synthetic polymers, have been previously designed to deliver drugs. One such synthetic polymer is polyethylene glycol (PEG). PEG is a hydrophilic and hygroscopic polymer that forms a “water cage” around the drug, which then provides steric repulsion from blood components and prevents both its opsonization and enzymatic degradation. This “stealth” property of PEG improves solubility and stability of drugs, and reduces their premature clearance from the subject, making PEGylation — the process of attaching drugs to PEG — an important method in the pharmaceutical industry. In recent years, a new class of zwitterionic synthetic polymers, polymers with alternating cationic and anionic groups in their monomer, has

demonstrated similar stealth properties. There are, however, three major shortcomings that undermine the reliability of synthetic polymers as drug delivery vehicles. First, it is well documented that repeated exposure to PEG can produce PEG-specific antibodies that trigger adverse immune responses. Second, synthetic polymers are non-biodegradable, and their effect *in vivo* post drug delivery is not well understood. Third, synthetic polymers are polydisperse in that each batch is composed of chains with different molecular weights. This polydispersity, which is intrinsic in synthetic polymers, can lead to a population of drug conjugates with different biological properties, especially with respect to the half-life and immunogenicity. There is a need in the art for efficient delivery of drugs with improved biocompatibility, solubility, stability and half-life, and reduced toxicity.

SUMMARY

[0005] In one aspect, provided herein are conjugates comprising: (a) a polypeptide comprising one or more charged motifs, each charged motif independently having an amino acid sequence consisting of SEQ ID NO: 1 (VPX₁X₂G), wherein X₁ is a negatively or positively charged amino acid, and wherein X₂ is the other of a negatively or positively charged amino acid; and (b) one or more drug molecules attached to the polypeptide.

[0006] In some embodiments, the polypeptide includes a plurality of charged motifs. In some embodiments, the plurality of charged motifs is repeated in tandem. In some embodiments, the polypeptide further includes one or more uncharged motifs, each uncharged motif independently having an amino acid sequence consisting of SEQ ID NO: 3 (VPGXG), wherein X is any amino acid except proline. In some embodiments, the polypeptide includes a plurality of uncharged motifs. In some embodiments, the plurality of uncharged motifs is repeated in tandem. In some embodiments, one or more uncharged motifs are positioned between at least two adjacent charged motifs of the polypeptide.

[0007] In some embodiments, the polypeptide includes the amino acid sequence of SEQ ID NO: 2 (VPX₁X₂G)_n, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, and n is an integer greater than or equal to 1. In some embodiments, the polypeptide includes the amino acid sequence of SEQ ID NO: 4 (VPGXG)_n, wherein X is any amino acid except proline, and n is an integer greater than or equal to 1. In some embodiments, the polypeptide includes the amino acid sequence of SEQ ID NO: 5 (VPX₁X₂G)_n(VPGXG)_m, wherein X₁ is a negatively or positively charged amino acid, X₂

is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1. In some embodiments, the polypeptide includes the amino acid sequence of SEQ ID NO: 6 (VPGXG)_m(VPX₁X₂G)_n, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1. In some embodiments, the polypeptide includes the amino acid sequence of SEQ ID NO: 7 {(VPX₁X₂G)(VPGXG)}_b, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and b is an integer greater than or equal to 1. In some embodiments, X₁ is a negatively charged amino acid, and wherein X₂ is a positively charged amino acid. In some embodiments, X₁ is a positively charged amino acid, and wherein X₂ is a negatively charged amino acid. In some embodiments, the negatively charged amino acid is independently selected from glutamic acid and aspartic acid. In some embodiments, the positively charged amino acid is independently selected from lysine and arginine. In some embodiments, X is any amino acid except proline. In some embodiments, X is selected from arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan. In some embodiments, X is selected from glycine and valine.

[0008] In some embodiments, the polypeptide further includes a linker. In some embodiments, the linker includes one or more cysteines. In some embodiments, the linker includes an amino acid sequence selected from SEQ ID NO: (GGC), SEQ ID NO: ((GGC)₈), SEQ ID NO: ((G₄S)₃), and SEQ ID NO: ((VPGXG)₁₆ wherein X is valine or cysteine present in a ratio of 1:1). In some embodiments, the linker is positioned at the C-terminus, at the N-terminus, or at both C- and N-termini of the polypeptide. In some embodiments, the one or more drug molecules are attached to the polypeptide via the linker. In some embodiments, the drug molecule is attached to the polypeptide through a thiol reactive group in the linker. In some embodiments, the one or more drug molecules are selected from a small molecule, nucleotide, polynucleotide, peptide, protein, carbohydrate, and a combination thereof. In some embodiments, the drug molecule includes a small molecule. In some embodiments, the drug molecule includes a protein. In some embodiments, the drug molecule includes a cancer therapeutic. In some embodiments, the drug molecule includes an antibody. In some

embodiments, the drug molecule includes a paclitaxel. In some embodiments, the drug molecule includes Tn3 (TRAIL superagonist). In some embodiments, the conjugate is prepared for administration to a subject. In some embodiments, the polypeptide of the conjugate is recombinantly expressed. In some embodiments, the conjugate is recombinantly expressed.

[0009] In another aspect, provided herein are compositions comprising the conjugate as detailed herein.

[0010] In another aspect, provided herein are polynucleotides encoding the polypeptide as detailed herein. In another aspect, provided herein are polynucleotides encoding the conjugate as detailed herein. In another aspect, provided herein are vectors comprising the polynucleotide.

[0011] In another aspect, provided herein are methods of delivering a drug molecule to a subject, the method comprising administering the conjugate as detailed herein to the subject.

[0012] In another aspect, provided herein are methods of treating a subject having a disease or disorder, the method comprising administering the conjugate as detailed herein to the subject.

[0013] In another aspect, provided herein are methods of determining the presence of a target in a sample, the method comprising: contacting the sample with the conjugate as detailed herein under conditions to allow a complex to form between the drug molecule and the target in the sample; and detecting the presence of the complex, wherein presence of the complex is indicative of the target in the sample.

[0014] In some embodiments, the sample is obtained from a subject and the method further includes diagnosing a disease, prognosticating, or assessing the efficacy of a treatment of the subject. In some embodiments, when the method further includes assessing the efficacy of a treatment of the subject, then the method further includes modifying the treatment of the subject as needed to improve efficacy. In another aspect, provided herein are methods of diagnosing a disease in a subject, the method comprising: contacting a sample from the subject with the conjugate as detailed herein under conditions to allow a complex to form between the drug molecule and a target in the sample; determining the level of the target in the sample, wherein level of the complex is indicative of the level of the target in the sample; and comparing the level of the target in the sample to a control level of the target, wherein a level of the target different

from the control level indicates disease in the subject. In some embodiments, the control level corresponds to the level in the subject at a time point before or during the period when the subject has begun treatment, and wherein the sample is taken from the subject at a later time point. In some embodiments, the sample is taken from the subject at a time point during the period when the subject is undergoing treatment, and wherein the control level corresponds to a disease-free level or to the level at a time point before the period when the subject has begun treatment. In some embodiments, the method further includes modifying the treatment or administering a different treatment to the subject when the treatment is determined to be ineffective in treating the disease. In some embodiments, the conjugate is labeled with a reporter. In some embodiments, the conjugate is administered to the subject intravenously, intraarterially, intraperitoneally, or intratumorally. In some embodiments, the conjugate has reduced antigenicity relative to the drug molecule conjugated to polyethylene glycol (PEG). In some embodiments, the conjugate has reduced immunogenicity relative to the drug molecule conjugated to polyethylene glycol (PEG). In some embodiments, the disease is selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorder. In some embodiments, the disease includes cancer. In some embodiments, the cancer is selected from breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer. In some embodiments, the cancer includes breast cancer.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 shows possible architectures and sequences of ZiPPs. (A) Homopolymer. (B) Diblock polymer. (C) Multiblock polymer. (D) Possible sequences of the charged motif.

[0016] FIG. 2 shows the characterization of ZiPPs. The ZiPP constructs used were 120 repeats of the pentapeptide zwitterionic motif. (A) SDS page analysis of purified ZiPP constructs. (B) Representative MALDI spectra for (VPKDG)₁₂₀ and (VPRDG)₁₂₀ confirmed the MW of purified ZiPP constructs (MW=60.5 kDa, MW=63.8 kDa, respectively). (C) Hydrodynamic radius measured using Dynamic Light Scattering showed well hydrated ZiPPs compared to ELP controls. (D) CD-Spectra of ZiPPs showed negative ellipticity in low wavelength and slightly

positive ellipticity in higher wavelength, which is typical of a disordered structure like ELPs. (E) Native PAGE gel showed that ZiPPs did not interact with albumin.

[0017] FIG. 3 shows the plasma pharmacokinetics of ELP (VPGAG) and ZiPPs when injected intravenously. (A) The experimental design. (B) Plasma concentrations as a function of time post-injection. (C) Area under the curve (AUC) for each conjugate. (D) Elimination half-life for each conjugate.

[0018] FIG. 4 shows the plasma pharmacokinetics of ELP (VPGAG) and ZiPPs when injected subcutaneously. (A) The experimental design. (B) Plasma concentrations as a function of time post-injection. (C) AUC for each conjugate.

[0019] FIG. 5 shows the characterization of ZiPP-PTX conjugate. (A) Design schematics of ZiPP paclitaxel (PTX) nanoparticles. Paclitaxel was chemically conjugated to the 8 C-terminal residues via a pH sensitive linker. (B) Dynamic and static light data after PTX conjugation shows that ZiPPs self-assembled into micelles of 58 nm radius with aggregation number of 26 per micelle. The form factor (ρ)—calculated as R_g/R_h —was 0.82, which denotes formation of spherical micelles. MALDI-MS of ZiPP and ZiPP+PTX conjugate showed that there were 3.2-4 drugs per polymer chain. (C) Cell viability for ZiPP-PTX, ELP-PTX, and free PTX in MDA-MB-231 triple negative breast cancer cell line after 72 hours of treatment.

[0020] FIG. 6 shows Zippylated proteins. (A) Design overview for ZiPP fusion protein with $(Tn3)_6$. (B) SDS-PAGE analysis of affinity purified samples of $(Tn3)_6$ with various lengths of ZiPP that were recombinantly expressed in *E. coli*. (C) Cytotoxicity assay against Colo205 (colon cancer cell) and calculated IC_{50} values.

[0021] FIG. 7 shows the characterization of ZiPPs. The ZiPP constructs used were 80 repeats of the pentapeptide zwitterionic motif. (A) SDS page analysis of purified ZiPP constructs. The 50 kD and 75 kD ladder is marked as a reference molecular weight, however, ladders used in SDS-PAGE are from globular proteins and hence are not directly comparable to unstructured ZiPPs. (B) Representative MALDI spectra for $(VPREG)_{80}$ and $(VPKEG)_{80}$ confirmed the molecular weight of the purified ZiPP constructs (MW=44.1 kDa, MW=41.8 kDa, respectively). (C) CD-Spectra of ZiPPs showed negative ellipticity in low wavelength and slightly positive ellipticity in higher wavelength, which is typical of a disordered structure like ELPs.

DETAILED DESCRIPTION

[0022] Provided herein are compositions and methods for delivering drug molecules to a subject. The compositions and methods include a conjugate including a polypeptide and a drug molecule attached thereto. The polypeptide includes both positively and negatively charged amino acids. The compositions and methods detailed herein may overcome previous challenges in drug delivery including limitations on biocompatibility, solubility, stability and half-life, immunogenicity, and antigenicity. The constructs detailed herein may use a hydrophilicity principle to provide a “water cage” around the conjugate to sterically shield the conjugate from degradation. The conjugates thereby increase the stability and solubility of the conjugated therapeutics and improve their *in vivo* efficacy. The conjugates may allow for the treatment of disease by effectively delivering drugs to treat the disease. In some embodiments wherein the drug binds a target, the conjugates may also be used to detect the target, detect or diagnose disease, and/or determine the efficacy of a treatment. The conjugates detailed herein may also be produced by genetic engineering, thereby facilitating their design and manipulation with precision, lower toxicity, better biocompatibility, and improved biodegradability.

1. Definitions

[0023] The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “and,” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of,” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.

[0024] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described

herein can be used in practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

[0026] The term “about” as used herein as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term “about” refers to a range of values that fall within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0027] “Amino acid” as used herein refers to naturally occurring and non-natural synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code. Amino acids can be referred to herein by either their commonly known three-letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Amino acids include the side chain and polypeptide backbone portions.

[0028] As used herein, the term “biomarker” refers to a naturally occurring biological molecule present in a subject at varying concentrations that is useful in identifying and/or classifying a disease or a condition. The biomarker can include genes, proteins, polynucleotides, nucleic acids, ribonucleic acids, polypeptides, or other biological molecules used as an indicator or marker for disease. In some embodiments, the biomarker comprises a disease marker. For example, the biomarker can be a gene that is upregulated or downregulated in a subject that has a disease. As another example, the biomarker can be a polypeptide whose level is increased or decreased in a subject that has a disease or risk of developing a disease. In some embodiments, the biomarker comprises a small molecule. In some embodiments, the biomarker comprises a polypeptide.

[0029] The terms “control,” “reference level,” and “reference” are used herein interchangeably. The reference level may be a predetermined value or range, which is employed as a benchmark against which to assess the measured result. “Control group” as used herein refers to a group of control subjects. The predetermined level may be a cutoff

value from a control group. The predetermined level may be an average from a control group. Cutoff values (or predetermined cutoff values) may be determined by Adaptive Index Model (AIM) methodology. Cutoff values (or predetermined cutoff values) may be determined by a receiver operating curve (ROC) analysis from biological samples of the patient group. ROC analysis, as generally known in the biological arts, is a determination of the ability of a test to discriminate one condition from another, e.g., to determine the performance of each marker in identifying a patient having CRC. A description of ROC analysis is provided in P.J. Heagerty et al. (*Biometrics* **2000**, *56*, 337-44), the disclosure of which is hereby incorporated by reference in its entirety. Alternatively, cutoff values may be determined by a quartile analysis of biological samples of a patient group. For example, a cutoff value may be determined by selecting a value that corresponds to any value in the 25th-75th percentile range, preferably a value that corresponds to the 25th percentile, the 50th percentile or the 75th percentile, and more preferably the 75th percentile. Such statistical analyses may be performed using any method known in the art and can be implemented through any number of commercially available software packages (e.g., from Analyse-it Software Ltd., Leeds, UK; StataCorp LP, College Station, TX; SAS Institute Inc., Cary, NC.). The healthy or normal levels or ranges for a target or for a protein activity may be defined in accordance with standard practice. A control may be a subject, or a sample therefrom, whose disease state is known. The subject, or sample therefrom, may be healthy, diseased, diseased prior to treatment, diseased during treatment, or diseased after treatment, or a combination thereof.

[0030] The term “expression vector” indicates a plasmid, a virus or another medium, known in the art, into which a nucleic acid sequence for encoding a desired protein can be inserted or introduced.

[0031] The term “host cell” is a cell that is susceptible to transformation, transfection, transduction, conjugation, and the like with a nucleic acid construct or expression vector. Host cells can be derived from plants, bacteria, yeast, fungi, insects, animals, etc. In some embodiments, the host cell includes *Escherichia coli*.

[0032] “Monodisperse” or “monodispersion” refers to a property of a plurality of conjugates, or polypeptides thereof, wherein each have about the same molecular weight. Genetically encoded synthesis of a conjugate may facilitate precise control of the molecular weight. Molecular weight is a factor that affects a molecule’s circulation time *in vivo*, or its half-life.

[0033] “Opsonization” refers to the molecular mechanism whereby molecules, microbes, or apoptotic cells are chemically modified to have stronger interactions with cell surface receptors on phagocytes and natural killer (NK) cells. An antigen on the molecules, microbes, or apoptotic cell is coated in opsonins. The opsonins enhance binding to immune cells such as macrophages and neutrophils. Opsonization also mediates phagocytosis via signal cascades from cell surface receptors.

[0034] “Synthetic polymer” refers to a polymer which is produced from at least one monomer by a chemical process. A synthetic polymer is not produced directly by a living organism. Synthetic polymers include a homopolymer, heteropolymer, block polymer, copolymer, ter-polymer, etc., and blends, combinations and mixtures thereof. Examples of synthetic polymers include, but are not limited to, functionalized polymers, such as a polymer comprising 5-vinyltetrazole monomer units and having a molecular weight distribution less than 2.0. A synthetic polymer may be or contain one or more of a star block copolymer, a linear polymer, a branched polymer, a hyperbranched polymer, a dendritic polymer, a comb polymer, a graft polymer, a brush polymer, a bottle-brush copolymer and a crosslinked structure, such as a block copolymer comprising a block of 5-vinyltetrazole monomer units. Synthetic polymers include, without limitation, polyesters, poly(meth)acrylamides, poly(meth)acrylates, polyethers, polystyrenes, polynorbornenes and monomers that have unsaturated bonds. For example, amphiphilic comb polymers are described in U.S. Patent Application Publication No. 2007/0087114 and in U.S. Patent No. 6,207,749 to Mayes et al., the disclosure of each of which is herein incorporated by reference in its entirety. The amphiphilic comb-type polymers may be present in the form of copolymers, containing a backbone formed of a hydrophobic, water-insoluble polymer and side chains formed of short, hydrophilic non-cell binding polymers. Examples of other synthetic polymers include, but are not limited to, polyalkylenes such as polyethylene and polypropylene and polyethyleneglycol (PEG); polychloroprene; polyvinyl ethers; such as poly(vinyl acetate); polyvinyl halides such as poly(vinyl chloride); polysiloxanes; polystyrenes; polyurethanes; polyacrylates; such as poly(methyl (meth)acrylate), poly(ethyl (meth)acrylate), poly(n-butyl(meth)acrylate), poly(isobutyl (meth)acrylate), poly(tert-butyl (meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl (meth)acrylate), poly(lauryl (meth)acrylate), poly(phenyl (meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate); polyacrylamides such as poly(acrylamide), poly(methacrylamide), poly(ethyl acrylamide), poly(ethyl methacrylamide), poly(N-isopropyl acrylamide), poly(n, iso, and tert-butyl acrylamide); and copolymers and mixtures thereof.

These synthetic polymers may include useful derivatives, including synthetic polymers having substitutions, additions of chemical groups, for example, alkyl groups, alkylene groups, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art. The synthetic polymers may include zwitterionic polymers such as, for example, polyphosphorycholine, polycarboxybetaine, and polysulfobetaine. The synthetic polymers may have side chains of betaine, carboxybetaine, sulfobetaine, oligoethylene glycol (OEG), sarcosine or polyethyleneglycol (PEG).

[0035] “Polynucleotide” as used herein can be single stranded or double stranded, or can contain portions of both double stranded and single stranded sequence. The polynucleotide can be nucleic acid, natural or synthetic, DNA, genomic DNA, cDNA, RNA, or a hybrid, where the polynucleotide can contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine. Polynucleotides can be obtained by chemical synthesis methods or by recombinant methods.

[0036] A “peptide” or “polypeptide” is a linked sequence of two or more amino acids linked by peptide bonds. The polypeptide can be natural, synthetic, or a modification or combination of natural and synthetic. Peptides and polypeptides include proteins such as binding proteins, receptors, and antibodies. The terms “polypeptide”, “protein,” and “peptide” are used interchangeably herein. “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains, e.g., enzymatic domains, extracellular domains, transmembrane domains, pore domains, and cytoplasmic tail domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Exemplary domains include domains with enzymatic activity or ligand binding activity. Typical domains are made up of sections of lesser organization such as stretches of beta-sheet and alpha-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. A “motif” is a portion of a polypeptide sequence and includes at least two amino acids. A motif may be 2 to 20, 2 to 15, or 2 to 10 amino acids in length. In some embodiments, a motif includes 3, 4, 5, 6, or 7 sequential amino acids.

[0037] “Pharmacokinetics” as used herein refers the circulation of drugs in the body and its bioavailability, distribution, and excretion.

[0038] “Recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed, or not expressed at all.

[0039] “Reporter,” “reporter group,” “label,” and “detectable label” are used interchangeably herein. The reporter is capable of generating a detectable signal. The label can produce a signal that is detectable by visual or instrumental means. A variety of reporter groups can be used, differing in the physical nature of signal transduction (e.g., fluorescence, electrochemical, nuclear magnetic resonance (NMR), and electron paramagnetic resonance (EPR)) and in the chemical nature of the reporter group. Various reporters include signal-producing substances, such as chromagens, fluorescent compounds, chemiluminescent compounds, radioactive compounds, and the like. In some embodiments, the reporter comprises a radiolabel. Reporters may include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein. In some embodiments, the signal from the reporter is a fluorescent signal. The reporter may comprise a fluorophore. Examples of fluorophores include, but are not limited to, acrylodan (6-acryloyl 1-2-dimethylaminonaphthalene), badan (6-bromo-acetyl-2-dimethylamino-naphthalene), rhodamine, naphthalene, dansyl aziridine, 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino]-7-nitrobenz-2-oxa-1,3-diazole ester (IANBDE), 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino-7-nitrobenz-2-oxa-1,3-diazole (IANBDA), fluorescein, dipyrrometheneboron difluoride (BODIPY), 4-nitrobenzo[c][1,2,5]oxadiazole (NBD), Alexa fluorescent dyes, and derivatives thereof. Fluorescein derivatives may include, for example, 5-fluorescein, 6-carboxyfluorescein, 3'6-carboxyfluorescein, 5(6)-carboxyfluorescein, 6-hexachlorofluorescein, 6-tetrachlorofluorescein, fluorescein, and isothiocyanate.

[0040] “Sample” or “test sample” as used herein can mean any sample in which the presence and/or level of a target is to be detected or determined. Samples may include liquids, solutions, emulsions, or suspensions. Samples may include a medical sample. Samples may include any biological fluid or tissue, such as blood, whole blood, fractions of blood such as

plasma and serum, muscle, interstitial fluid, sweat, saliva, urine, tears, synovial fluid, bone marrow, cerebrospinal fluid, nasal secretions, sputum, amniotic fluid, bronchoalveolar lavage fluid, gastric lavage, emesis, fecal matter, lung tissue, peripheral blood mononuclear cells, total white blood cells, lymph node cells, spleen cells, tonsil cells, cancer cells, tumor cells, bile, digestive fluid, skin, or combinations thereof. In some embodiments, the sample comprises an aliquot. In other embodiments, the sample comprises a biological fluid. Samples can be obtained by any means known in the art. The sample can be used directly as obtained from a patient or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or otherwise as is known in the art.

[0041] The term “sensitivity” as used herein refers to the number of true positives divided by the number of true positives plus the number of false negatives, where sensitivity (“sens”) may be within the range of $0 < \text{sens} < 1$. Ideally, method embodiments herein have the number of false negatives equaling zero or close to equaling zero, so that no subject is wrongly identified as not having a disease when they indeed have the disease. Conversely, an assessment often is made of the ability of a prediction algorithm to classify negatives correctly, a complementary measurement to sensitivity.

[0042] The term “specificity” as used herein refers to the number of true negatives divided by the number of true negatives plus the number of false positives, where specificity (“spec”) may be within the range of $0 < \text{spec} < 1$. Ideally, the methods described herein have the number of false positives equaling zero or close to equaling zero, so that no subject is wrongly identified as having a disease when they do not in fact have disease. Hence, a method that has both sensitivity and specificity equaling one, or 100%, is preferred.

[0043] By “specifically binds,” it is generally meant that a polypeptide binds to a target when it binds to that target more readily than it would bind to a random, unrelated target.

[0044] “Stealth” or “stealth polymer” refers to a conjugate, or to the polypeptide thereof, that can remain undetected by immune cells in the bloodstream for a prolonged period of time. Stealth polymers are at least partially resistant to enzymatic degradation of the conjugate, or to the polypeptide thereof, such as by proteases, and opsonization, which is a common method used by immune system to recognize foreign particles. Accordingly, stealth polymers may have

one or more of reduced antigenicity, reduced immunogenicity, increased stability, increased half-life, and increased bioavailability relative to other polymers, conjugates, non-stealth polymers, and/or non-stealth conjugates. The ability to delay, reduce, or prevent opsonization, recognition by the immune system, or clearance of a conjugate (or the polypeptide or drug molecules thereof) from the body may be referred to herein as a stealth property.

[0045] “Subject” as used herein can mean a mammal that wants or is in need of the herein described conjugates or fusion proteins. The subject may be a human or a non-human animal. The subject may be a mammal. The mammal may be a primate or a non-primate. The mammal can be a primate such as a human; a non-primate such as, for example, dog, cat, horse, cow, pig, mouse, rat, camel, llama, goat, rabbit, sheep, hamster, and guinea pig; or non-human primate such as, for example, monkey, chimpanzee, gorilla, orangutan, and gibbon. The subject may be of any age or stage of development, such as, for example, an adult, an adolescent, or an infant.

[0046] “Target” as used herein can refer to an entity that a drug molecule binds. A target may include, for example, a small molecule, a protein, a polypeptide, a polynucleotide, a carbohydrate, or a combination thereof.

[0047] “Transition” or “phase transition” refers to the aggregation of the thermally responsive polypeptides. Phase transition occurs sharply and reversibly at a specific temperature called the lower critical solution temperature (LCST) or the inverse transition temperature T_t . Below the transition temperature, the thermally responsive polypeptide (or a polypeptide comprising a thermally responsive polypeptide) is highly soluble. Upon heating past the transition temperature, the thermally responsive polypeptides hydrophobically collapse and aggregate, forming a separate, gel-like phase. “Inverse transition cycling” refers to a protein purification method for thermally responsive polypeptides (or a polypeptide comprising a thermally responsive polypeptide). The protein purification method may involve the use of thermally responsive polypeptide’s reversible phase transition behavior to cycle the solution through soluble and insoluble phases, thereby removing contaminants.

[0048] “Treatment” or “treating,” when referring to protection of a subject from a disease, means preventing, suppressing, repressing, ameliorating, or completely eliminating the disease. Preventing the disease involves administering a composition of the present invention to a subject prior to onset of the disease. Suppressing the disease involves administering a

composition of the present invention to a subject after induction of the disease but before its clinical appearance. Reprising or ameliorating the disease involves administering a composition of the present invention to a subject after clinical appearance of the disease.

[0049] “Substantially identical” can mean that a first and second amino acid sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 amino acids.

[0050] “Variant” as used herein with respect to a polynucleotide means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a polynucleotide that is substantially identical to a referenced polynucleotide or the complement thereof; or (iv) a polynucleotide that hybridizes under stringent conditions to the referenced polynucleotide, complement thereof, or a sequences substantially identical thereto.

[0051] A “variant” can further be defined as a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Representative examples of “biological activity” include the ability to be bound by a specific antibody or polypeptide or to promote an immune response. Variant can mean a substantially identical sequence. Variant can mean a functional fragment thereof. Variant can also mean multiple copies of a polypeptide. The multiple copies can be in tandem or separated by a linker. Variant can also mean a polypeptide with an amino acid sequence that is substantially identical to a referenced polypeptide with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydrophobic index of amino acids. See Kyte et al., *J. Mol. Biol.* **1982**, 157, 105-132. The hydrophobic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydrophobic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydrophobic indices of ± 2 are substituted. The hydrophobicity of amino acids can also be used to reveal substitutions that would result in polypeptides retaining biological function. A consideration of the hydrophilicity of

amino acids in the context of a polypeptide permits calculation of the greatest local average hydrophilicity of that polypeptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity, as discussed in U.S. Patent No. 4,554,101, which is fully incorporated herein by reference. Substitution of amino acids having similar hydrophilicity values can result in polypeptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions can be performed with amino acids having hydrophilicity values within ± 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.

[0052] A variant can be a polynucleotide sequence that is substantially identical over the full length of the full gene sequence or a fragment thereof. The polynucleotide sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof. A variant can be an amino acid sequence that is substantially identical over the full length of the amino acid sequence or fragment thereof. The amino acid sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the amino acid sequence or a fragment thereof.

[0053] "Water cage" refers to water molecules surrounding a molecule and interacting ionically with the molecule. The molecule may be, for example, a polypeptide, a ZiPP, a drug molecule, or a conjugate. When the molecule is in a solution, for example, the molecule forms ionic interactions with the surrounding water molecules such that a water cage is formed around it. For example, the positively and negatively charged amino acids of a polypeptide may form ionic interactions with water molecules around it in solution. The solution may include, for example, a subject's plasma or blood or other bodily fluid. Ionic interactions are stronger than hydrogen bonds or other intermolecular attractions and need more energy to become perturbed. In some embodiments, the water cage can shield the molecule (for example, a polypeptide, a ZiPP, a drug molecule, or a conjugate) from degradation or opsonization. A water cage may confer a stealth property to a molecule.

[0054] “Zwitterionic” or “zwitterion” refers to a molecule with net charge of zero, but including negative and positive charges on independent individual atoms within the molecule. The charged atoms are joined by one or more covalent bonds. A polypeptide may be zwitterionic.

2. Conjugate

[0055] The conjugate includes a polypeptide and one or more drug molecules attached to the polypeptide. The conjugate may further include at least one linker. The conjugates are considered stealth polymers for drug delivery.

a. Polypeptide

[0056] The polypeptide comprises one or more charged motifs. The charged motif includes one or more positively charged amino acids and one or more negatively charged amino acids, wherein the positively charged amino acids and negatively charged amino acids are present in a ratio of 1:1. In some embodiments, the net charge of the motif is neutral. In some embodiments, the charged motif is a zwitterionic motif. The positively charged amino acids within one motif may be the same or different. The negatively charged amino acids within one motif may be the same or different. As used herein, the charge of an amino acid (positive and/or negative) refers to the charge of the amino acid side chain. A charged amino acid is positively and/or negatively charged at neutral pH, at physiological pH, or at the local pH within the protein fold, or a combination thereof. The charged motif may further include one or more uncharged amino acids. In some embodiments, the charged motif has an amino acid sequence of VPX_1X_2G (SEQ ID NO: 1), wherein X_1 is a negatively or positively charged amino acid, and wherein X_2 is the other of a negatively or positively charged amino acid. A polypeptide comprising one or more charged motifs may be a zwitterionic polypeptide (ZiPP). ZiPPs are overall neutral polypeptides that include both amino acids with negative charge and amino acids with positive charge.

[0057] In some embodiments, the polypeptide comprises a plurality of charged motifs. The plurality of charged motifs may be repeated. In some embodiments, polypeptide comprises the amino acid sequence of $(VPX_1X_2G)_n$ (SEQ ID NO: 2), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, and n is an integer greater than or equal to 1. X_1 may be the same or different between adjacent motifs.

X_2 may be the same or different between adjacent motifs. In some embodiments, n is an integer less than or equal to about 100, 200, 300, 400, or 500. In some embodiments, n is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In some embodiments, n is an integer from about 10 to about 500, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 500, from about 1 to about 200, from about 1 to about 100, or from about 1 to about 50. In some embodiments, n is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500. In some embodiments, a polypeptide comprising the amino acid sequence of $(VPX_1X_2G)_n$ (SEQ ID NO: 2), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, and n is an integer greater than or equal to 1, may be referred to as a homopolymer.

[0058] In some embodiments, the polypeptide includes one or more uncharged motifs in addition to the one or more charged motifs. The uncharged motif includes uncharged amino acids. In some embodiments, the uncharged motif does not include any charged amino acids. In some embodiments, the uncharged motif has an amino acid sequence consisting of $VPGXG$ (SEQ ID NO: 3), wherein X is any amino acid except proline.

[0059] A plurality of uncharged motifs may be repeated in tandem. In some embodiments, the polypeptide comprises the amino acid sequence of $(VPGXG)_n$ (SEQ ID NO: 4) in addition to the one or more charged motifs, wherein X is any amino acid except proline, and n is an integer greater than or equal to 1. In some embodiments, n is an integer less than or equal to about 100, 200, 300, 400, or 500. In some embodiments, n is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In some embodiments, n is an integer from about 10 to about 500, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 500, from about 1 to about 200, from about 1 to about 100, or from about 1 to about 50. In some embodiments, n is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195,

200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500. In some embodiments, polypeptides comprising an uncharged motif having an amino acid sequence consisting of (VPGXG)_n (SEQ ID NO: 4) in addition to the one or more charged motifs, wherein X is any amino acid except proline, and n is an integer greater than or equal to 1, are referred to as elastin-like polypeptides (ELP).

[0060] The motifs of the polypeptide can be arranged in any number of possible ways. Examples of possible arrangements and architectures are shown in FIG. 1. In FIG. 1, the gray block denotes a positively charged amino acid while the black block denotes a negatively charged amino acid. FIG. 1A shows an example of a homopolymer, wherein each unit is a repeat of the pentapeptide sequence VPX₁X₂G (SEQ ID NO: 1), or charged motif. FIG. 1D shows possible sequences of VPX₁X₂G (SEQ ID NO: 1). FIG. 1B shows an example of a diblock polymer. In a diblock architecture, one block of polymer is made with a repeating charged motif, while the other part includes a repeating uncharged motif. FIG. 1C shows an example of a multiblock polymer, wherein the charged motifs and uncharged motifs are placed at different sites to increase diversity of the polymer. The particular number, identity, and arrangement of motifs may be designed to create a conjugate that can achieve an optimal level of solvation, create a water cage, and/or create a layer around itself to help improve the pharmacokinetics of the therapeutics or drug molecules. In some embodiments, the polypeptide is arranged to confer a stealth property to the polypeptide or conjugate. In some embodiments, one or more uncharged motifs are positioned between at least two adjacent charged motifs of the polypeptide. In some embodiments, the polypeptide includes a plurality of charged motifs repeated in tandem and a plurality of uncharged motifs repeated in tandem. In some embodiments, the plurality of charged motifs repeated in tandem are positioned C-terminal to the plurality of uncharged motifs repeated in tandem. In some embodiments, the plurality of charged motifs repeated in tandem are positioned N-terminal to the plurality of uncharged motifs repeated in tandem.

[0061] In some embodiments, the polypeptide comprises the amino acid sequence of (VPX₁X₂G)_n(VPGXG)_m (SEQ ID NO: 5), wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1. In some

embodiments, n is an integer less than or equal to about 100, 200, 300, 400, or 500. In some embodiments, n is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In some embodiments, n is an integer from about 10 to about 500, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 500, from about 1 to about 200, from about 1 to about 100, or from about 1 to about 50. In some embodiments, n is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500. In some embodiments, m is an integer less than or equal to about 100, 200, 300, 400, or 500. In some embodiments, m is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In some embodiments, m is an integer from about 10 to about 500, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 500, from about 1 to about 200, from about 1 to about 100, or from about 1 to about 50. In some embodiments, m is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500. In some embodiments, a polypeptide comprising the amino acid sequence of $(VPX_1X_2G)_n(VPGXG)_m$ (SEQ ID NO: 5), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1, may be referred to as a diblock polymer.

[0062] In some embodiments, the polypeptide comprises the amino acid sequence of $(VPGXG)_m(VPX_1X_2G)_n$ (SEQ ID NO: 6), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1. In some embodiments, n is an integer less than or equal to about 100, 200, 300, 400, or 500. In some embodiments, n is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In

some embodiments, n is an integer from about 10 to about 500, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 500, from about 1 to about 200, from about 1 to about 100, or from about 1 to about 50. In some embodiments, n is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500. In some embodiments, m is an integer less than or equal to about 100, 200, 300, 400, or 500. In some embodiments, m is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In some embodiments, m is an integer from about 10 to about 500, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 500, from about 1 to about 200, from about 1 to about 100, or from about 1 to about 50. In some embodiments, m is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500. In some embodiments, a polypeptide comprising the amino acid sequence of $(VPGXG)_m(VPX_1X_2G)_n$ (SEQ ID NO: 6), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1, may be referred to as a diblock polymer.

[0063] In some embodiments, the polypeptide comprises the amino acid sequence of $\{(VPX_1X_2G)(VPGXG)\}_b$ (SEQ ID NO: 7), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and b is an integer greater than or equal to 1. In some embodiments, b is an integer less than or equal to about 100, 200, or 300. In some embodiments, b is an integer greater than or equal to about 1, 10, 50, 100, 150, or 200. In some embodiments, b is an integer from about 10 to about 300, from about 10 to about 200, from about 10 to about 100, from about 10 to about 50, from about 1 to about 300, from about 1 to about 200, from about 1

to about 100, or from about 1 to about 50. In some embodiments, b is an integer equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, or 300. In some embodiments, a polypeptide comprising the amino acid sequence of $\{(VPX_1X_2G)(VPGXG)\}_b$ (SEQ ID NO: 7), wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and b is an integer greater than or equal to 1, may be referred to as a multiblock polymer.

[0064] In some embodiments, X_1 is a negatively charged amino acid, and X_2 is a positively charged amino acid. In some embodiments, X_1 is a positively charged amino acid, and X_2 is a negatively charged amino acid. In some embodiments, the negatively charged amino acid is independently selected from glutamic acid and aspartic acid. In some embodiments, the positively charged amino acid is independently selected from lysine and arginine. In some embodiments, X is selected from arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan. In some embodiments, X is selected from glycine and valine.

[0065] In some embodiments, the polypeptide is temperature-sensitive, which may also be referred to as thermally responsive. Thermally responsive polypeptides may have a phase transition. A thermally responsive polypeptide may impart a phase transition characteristic to the polypeptide and/or conjugate. Phase transition occurs sharply and reversibly at a specific temperature called the lower critical solution temperature (LCST) or the inverse transition temperature (Tt). "Phase transition" or "transition" may also refer to the aggregation of the thermally responsive polypeptide. Below the transition temperature (LCST or Tt), the thermally responsive polypeptides (or polypeptides comprising a thermally responsive polypeptide) may be highly soluble. Upon heating above the transition temperature, thermally responsive polypeptides hydrophobically may collapse and aggregate, forming a separate, gel-like phase or insoluble hydrophobic aggregates. The thermal responsive property of the polypeptide may be utilized in purification of the polypeptide and/or conjugate according to a method referred to as "inverse transition cycling. Phase transition may also be triggered using kosmotropic salts, such as, for example, ammonium sulfate. Sodium chloride, for example, may be used with the

kosmotropic salt. The kosmotropic salt may be added to a solution comprising the polypeptide and/or conjugate, with the kosmotropic salt being added until the polypeptide and/or conjugate forms aggregates or is precipitated out of solution. The aggregates may be pelleted by centrifugation and resuspended in a second solution or buffer. Aggregates of the polypeptide and/or conjugate may re-solubilize into solution once cooled below their T_t or when the kosmotropic salt is removed from the solution. In some embodiments, the conjugates are purified without any chromatographic purification. In some embodiments, the conjugates are generated recombinantly and purified from bacterial culture, such as, for example, from *E. coli*.

b. Drug Molecule

[0066] The conjugate may include one or more drug molecules. The drug molecule may be a therapeutic. In some embodiments, the drug molecule is selected from a small molecule, nucleotide, polynucleotide, protein, polypeptide, carbohydrate, and a combination thereof. In some embodiments, the drug molecule comprises a small molecule. In some embodiments, the drug molecule comprises a protein. In some embodiments, the drug molecule comprises a cancer therapeutic. In some embodiments, the drug molecule comprises an antibody. In some embodiments, the drug molecule comprises Tn3 (TRAIL superagonist). In some embodiments, the drug molecule is attached to a cysteine of the polypeptide of the conjugate.

[0067] The conjugate may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 drug molecules. The conjugate may include at least about 1, at least about 2, or at least about 3 drug molecules. The conjugate may include less than about 10, less than about 8, or less than about 5 drug molecules. In some embodiments, the conjugate includes 1 drug molecule. In some embodiments, the conjugate includes 1 drug molecule per polypeptide of the conjugate. In some embodiments, the conjugate includes 1-10 drug molecules. In some embodiments, the conjugate includes 2-5 drug molecules.

c. Linker

[0068] In some embodiments, the conjugate further includes at least one linker. In some embodiments, the conjugate includes more than one linker. In such embodiments, the linkers may be the same or different from one another. The conjugate may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 linkers. The conjugate may include less than 20, less than 15, less than 10, or less than 5 linkers. The conjugate may include between 1 and 20, between 5 and 15, or between 1 and 5

linkers. The linker may be positioned in at the C-terminus of the polypeptide, at the N-terminus of the polypeptide, or at both the N- and C-termini of the polypeptide. In some embodiments, the linker may be positioned anywhere within a polypeptide sequence. Multiple linkers may be positioned adjacent to one another.

[0069] The linker may be a polypeptide of any amino acid sequence and length. The linker may act as a spacer peptide. In some embodiments, the linker comprises charged amino acids. In some embodiments, the linker comprises uncharged amino acids. In some embodiments, the linker is flexible. In some embodiments, the linker comprises one or more cysteines. In some embodiments, the linker comprises an amino acid sequence selected from SEQ ID NO: 8 (GGC), SEQ ID NO: 9 ((GGC)₈), SEQ ID NO: 10 ((G₄S)₃), and SEQ ID NO: 11 ((VPGXG)₁₆ wherein X is valine or cysteine present in a ratio of 1:1).

[0070] The linker may serve as an attachment site for the drug molecule to the polypeptide. The drug molecule may attach to the linker by any suitable means known in the art. The drug molecule may attach to the linker through a thiol reactive linking group. In some embodiments, the one or more drug molecules are attached to the polypeptide via the linker. In some embodiments, the drug molecule is attached to the polypeptide through a thiol reactive group in the linker.

3. Polynucleotides

[0071] Further provided are polynucleotides encoding the conjugates detailed herein. A vector may include the polynucleotide encoding the conjugates detailed herein. To obtain expression of a polypeptide, one may subclone the polynucleotide encoding the polypeptide into an expression vector that contains a promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. An example of a vector is pet24. Suitable bacterial promoters are well known in the art. Further provided is a host cell transformed or transfected with an expression vector comprising a polynucleotide encoding a conjugate as detailed herein. Bacterial expression systems for expressing the protein are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Paiva et al., *Gene* **1983**, 22, 229-235; Mosbach et al., *Nature* **1983**, 302, 543-545). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available. Retroviral expression systems can be used in the present invention. In some

embodiments, the conjugate comprises a polypeptide comprising an amino acid sequence of SEQ ID NOs: 12. In some embodiments, the conjugate comprises a polypeptide encoded by a polynucleotide sequence of SEQ ID NOs: 13.

[0072] The conjugate may be expressed recombinantly in a host cell according to one of skill in the art. The conjugate may be purified by any means known to one of skill in the art. For example, the conjugate may be purified using chromatography, such as liquid chromatography, size exclusion chromatography, or affinity chromatography, or a combination thereof. In some embodiments, the conjugate is purified without chromatography. In some embodiments, the conjugate is purified using inverse transition cycling.

4. Administration

[0073] A composition may comprise the conjugate. The conjugates as detailed above can be formulated into a composition in accordance with standard techniques well known to those skilled in the pharmaceutical art. The composition may be prepared for administration to a subject. Such compositions comprising a conjugate can be administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the age, sex, weight, and condition of the particular subject, and the route of administration.

[0074] The conjugate can be administered prophylactically or therapeutically. In prophylactic administration, the conjugate can be administered in an amount sufficient to induce a response. In therapeutic applications, the conjugates are administered to a subject in need thereof in an amount sufficient to elicit a therapeutic effect. An amount adequate to accomplish this is defined as “therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the particular composition of the conjugate regimen administered, the manner of administration, the stage and severity of the disease, the general state of health of the patient, and the judgment of the prescribing physician.

[0075] The conjugate can be administered by methods well known in the art as described in Donnelly et al. (*Ann. Rev. Immunol.* **1997**, *15*, 617-648); Felgner et al. (U.S. Patent No. 5,580,859, issued Dec. 3, 1996); Felgner (U.S. Patent No. 5,703,055, issued Dec. 30, 1997); and Carson et al. (U.S. Patent No. 5,679,647, issued Oct. 21, 1997), the contents of all of which are incorporated herein by reference in their entirety. The conjugate can be complexed to particles or beads that can be administered to an individual, for example, using a vaccine gun. One skilled in the art would know that the choice of a pharmaceutically acceptable carrier,

including a physiologically acceptable compound, depends, for example, on the route of administration.

[0076] The conjugates can be delivered via a variety of routes. Typical delivery routes include parenteral administration, e.g., intradermal, intramuscular or subcutaneous delivery. Other routes include oral administration, intranasal, intravaginal, transdermal, intravenous, intraarterial, intratumoral, intraperitoneal, and epidermal routes. In some embodiments, the conjugate is administered intravenously, intraarterially, or intraperitoneally to the subject.

[0077] The conjugate can be a liquid preparation such as a suspension, syrup, or elixir. The conjugate can be incorporated into liposomes, microspheres, or other polymer matrices (such as by a method described in Felgner et al., U.S. Patent No. 5,703,055; Gregoriadis, Liposome Technology, Vols. I to III (2nd ed. 1993), the contents of which are incorporated herein by reference in their entirety). Liposomes can consist of phospholipids or other lipids, and can be nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

[0078] The conjugate may be used as a vaccine. The vaccine can be administered via electroporation, such as by a method described in U.S. Patent No. 7,664,545, the contents of which are incorporated herein by reference. The electroporation can be by a method and/or apparatus described in U.S. Patent Nos. 6,302,874; 5,676,646; 6,241,701; 6,233,482; 6,216,034; 6,208,893; 6,192,270; 6,181,964; 6,150,148; 6,120,493; 6,096,020; 6,068,650; and 5,702,359, the contents of which are incorporated herein by reference in their entirety. The electroporation can be carried out via a minimally invasive device.

[0079] In some embodiments, the conjugate is administered in a controlled release formulation. The conjugate may be released into the circulation or a tumor, for example. In some embodiments, the conjugate may be released over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 1 week, at least about 1.5 weeks, at least about 2 weeks, at least about 2.5 weeks, at least about 3.5 weeks, at least about 4 weeks, or at least about 1 month.

5. Detection

[0080] As used herein, the term “detect” or “determine the presence of” refers to the qualitative measurement of undetectable, low, normal, or high concentrations of one or more conjugates bound to target. In some embodiments, the target may be a biomarker. Detection may include *in vitro*, *ex vivo*, or *in vivo* detection. Detection may include detecting the presence of one or more conjugates or targets versus the absence of the one or more conjugates or targets. Detection may also include quantification of the level of one or more conjugates or targets. The term “quantify” or “quantification” may be used interchangeably, and may refer to a process of determining the quantity or abundance of a substance (e.g., conjugate or target), whether relative or absolute. Any suitable method of detection falls within the general scope of the present disclosure. In some embodiments, the conjugate comprises a reporter attached thereto for detection. In some embodiments, the conjugate is labeled with a reporter. In some embodiments, detection of conjugate bound to target may be determined by methods including but not limited to, band intensity on a Western blot, flow cytometry, radiolabel imaging, cell binding assays, activity assays, SPR, immunoassay, or by various other methods known in the art.

[0081] In some embodiments, including those wherein the conjugate comprises an antibody for binding and/or detecting a target, any immunoassay may be utilized. The immunoassay may be an enzyme-linked immunoassay (ELISA), radioimmunoassay (RIA), a competitive inhibition assay, such as forward or reverse competitive inhibition assays, a fluorescence polarization assay, or a competitive binding assay, for example. The ELISA may be a sandwich ELISA. Specific immunological binding of the conjugate to the target can be detected via direct labels, attached to the conjugate or via indirect labels, such as alkaline phosphatase or horseradish peroxidase. The use of immobilized conjugates may be incorporated into the immunoassay. The conjugates may be immobilized onto a variety of supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate (such as microtiter wells), pieces of a solid substrate material, and the like. An assay strip can be prepared by coating the conjugate or plurality of conjugates in an array on a solid support. This strip can then be dipped into the test biological sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot.

6. Methods

a. Methods of Delivering a Drug Molecule

[0082] The present invention is directed to a method of delivering a drug molecule to a subject. The method may include administering the conjugate as described herein to the subject. In some embodiments, the conjugate has an improved property relative to the drug molecule alone or the drug molecule conjugated to a synthetic polymer such as polyethylene glycol (PEG), the improved property selected from, for example, stealth, biocompatibility, solubility, stability, half-life, retention in plasma, antigenicity, immunogenicity, monodispersion, or a combination thereof. In some embodiments, the conjugate is easily synthesized. In some embodiments, the conjugate is easily purified. In some embodiments, the easy synthesis and/or purification may lead to improved cost-effectiveness of the conjugates. In some embodiments, the conjugate, or polypeptide thereof, is genetically encoded, thereby facilitating the design of a conjugate with a precise molecular weight. In some embodiments, the molecular weight of the conjugate determines and/or affects its half-life *in vivo*. Being able to easily and precisely control the molecular weight of the conjugate may facilitate control of the half-life of the conjugate *in vivo*. In comparison, it may not be easy to control the molecular weight of synthetic polymers such as PEG. In some embodiments, the conjugate has reduced antigenicity relative to the drug molecule conjugated to a synthetic polymer such as polyethylene glycol (PEG). In some embodiments, the conjugate has reduced immunogenicity relative to the drug molecule conjugated to a synthetic polymer such as polyethylene glycol (PEG).

b. Methods of Treating a Disease

[0083] The present invention is directed to a method of treating a disease in a subject in need thereof. The method may comprise administering to the subject an effective amount of the conjugate as described herein. The disease may be, for example, cancer, a metabolic disease, an autoimmune disease, a cardiovascular disease, or an orthopedic disorder.

[0084] Metabolic disease may occur when abnormal chemical reactions in the body alter the normal metabolic process. Metabolic diseases may include, for example, insulin resistance, non-alcoholic fatty liver diseases, type 2 diabetes, insulin resistance diseases, cardiovascular diseases, arteriosclerosis, lipid-related metabolic disorders, hyperglycemia, hyperinsulinemia, hyperlipidemia, and glucose metabolic disorders.

[0085] Autoimmune diseases arise from an abnormal immune response of the body against substances and tissues normally present in the body. Autoimmune diseases may include, but are not limited to, lupus, rheumatoid arthritis, multiple sclerosis, insulin dependent diabetes mellitus, myasthenia gravis, Grave's disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, polyarteritis nodosa, myocarditis, psoriasis, Celiac disease, Crohn's disease, ulcerative colitis, and fibromyalgia.

[0086] Cardiovascular disease is a class of diseases that involve the heart or blood vessels. Cardiovascular diseases may include, for example, coronary artery diseases (CAD) such as angina and myocardial infarction (heart attack), stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

[0087] Orthopedic disorders or musculoskeletal disorders are injuries or pain in the body's joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck, and back. Orthopedic disorders may include degenerative diseases and inflammatory conditions that cause pain and impair normal activities. Orthopedic disorders may include, for example, carpal tunnel syndrome, epicondylitis, and tendinitis.

[0088] Cancers may include, but are not limited to, breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer, bone cancers, carcinomas, sarcomas, and soft tissue cancers. In some embodiments, the cancer is breast cancer.

c. Methods of Diagnosing a Disease

[0089] Provided herein are methods of diagnosing a disease. The methods may include administering to the subject a conjugate as described herein, and detecting binding of the conjugate to a target to determine presence of the target in the subject. The presence or absence of the target may indicate the disease in the subject. In other embodiments, the methods may include contacting a sample from the subject with a conjugate as described herein, determining the level of a target in the sample, and comparing the level of the target in

the sample to a control level of the target, wherein a level of the target different from the control level indicates disease in the subject. In some embodiments, detected levels of the target less than a control may indicate disease. In some embodiments, detected levels of the target greater than a control may indicate disease. In some embodiments, the disease is selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorders, as detailed above. In some embodiments, the target comprises a disease marker or biomarker.

d. Methods of Determining the Presence- of a Target

[0090] Provided herein are methods of determining the presence of a target in a sample. The methods may include contacting the sample with a conjugate as described herein under conditions to allow a complex to form between the conjugate and the target in the sample, and detecting the presence of the complex. Presence of the complex may be indicative of the target in the sample. The target may be a protein or a nucleic acid, for example. The protein may be a receptor or an antigen, for example. The antigen may be associated with a disease, for example. In some embodiments, the target comprises a biomarker. In some embodiments, the conjugate is labeled with a reporter for detection.

[0091] In some embodiments, the sample is obtained from a subject and the method further includes diagnosing, prognosticating, or assessing the efficacy of a treatment of the subject. When the method includes assessing the efficacy of a treatment of the subject, the method may further include modifying the treatment of the subject as needed to improve efficacy.

e. Methods of Determining the Effectiveness of a Treatment

[0092] Provided herein are methods of determining the effectiveness of a treatment for a disease in a subject in need thereof. The methods may include contacting a sample from the subject with a conjugate as detailed herein under conditions to allow a complex to form between the conjugate and a target in the sample, determining the level of the complex in the sample, wherein the level of the complex is indicative of the level of the target in the sample, and comparing the level of the target in the sample to a control level of the target, wherein if the level of the target is different from the control level, then the treatment is determined to be effective or ineffective in treating the disease.

[0093] Time points may include prior to onset of disease, prior to administration of a therapy, various time points during administration of a therapy, and after a therapy has concluded, or a combination thereof. Upon administration of the conjugate to the subject, the conjugate may bind a target, wherein the presence or absence of the target indicates the presence of the disease in the subject at the various time points. In some embodiments, the target comprises a disease marker or biomarker. Comparison of the binding of the conjugate to the target at various time points may indicate whether the disease has progressed, whether the diseased has advanced, whether a therapy is working to treat or prevent the disease, or a combination thereof.

[0094] In some embodiments, the control level corresponds to the level in the subject at a time point before or during the period when the subject has begun treatment, and the sample is taken from the subject at a later time point. In some embodiments, the sample is taken from the subject at a time point during the period when the subject is undergoing treatment, and the control level corresponds to a disease-free level or to the level at a time point before the period when the subject has begun treatment. In some embodiments, the method further includes modifying the treatment or administering a different treatment to the subject when the treatment is determined to be ineffective in treating the disease.

7. Examples

Example 1

Materials and Methods

[0095] ***Cloning.*** The synthetic genes for ZiPPs were assembled from chemically synthesized oligomers (IDT Inc.; Coralville, IA). The oligomers were cloned into a pET expression vector in *E. coli* using plasmid reconstruction recursive directional ligation (Pre-RDL) technique (McDaniel, J.R., et al. *Biomacromolecules*, **2010**, *11*, 944-952).

[0096] ***Expression and purification of ZiPPs by inverse transition cycling (ITC).*** ZiPPs were expressed from a pET expression vector in *E. coli*. All ZiPPs in aqueous solution show a reversible inverse phase transition. They go from being a soluble protein to insoluble hydrophobic aggregates when heated above their transition temperature (Tt). The same phenomena (phase separation) can be also triggered using kosmotropic salts. Aggregates of ZiPPs can re-solubilize into the solution once cooled below their Tt or when the salt is removed

from the solution. This thermally responsive property of ZiPP enables a simple non-chromatographic method for protein purification. This method of purification is called “inverse transition cycling” (ITC) (Meyer, D.E. and A. Chilkoti. *Nat. Biotech.* **1999**, *17*, 1112-1115; MacEwan, S.R., et al. *J. Vis. Exp.* **2014**, *88*, e51583).

[0097] In a typical purification of ZiPPs by ITC, *E. coli* cells from 1 L culture are recovered by centrifugation and re-suspended in cold PBS. The cells are then lysed by ultrasonic disruption at 4°C. The *E. coli* lysate is then centrifuged at 15,000xg to remove the cell wall and other cellular debris. ZiPPs are soluble proteins that are present in the soluble fraction (supernatant) of the cell lysate. Polyethylenimine is added to the supernatant of the cell lysate, and centrifuged at 14,000xg to pellet DNA and any remaining bacterial cell walls. ZiPPs are then purified from the supernatant by triggering phase separation using ammonium sulfate and sodium chloride, followed by centrifugation at 15,000xg for 15 minutes at 4°C. The pellet is then resuspended in cold PBS, and any insoluble matter is removed by a centrifugation step at 4°C for 10 min. These steps are repeated until homogeneity, which is confirmed by the appearance of a single band in SDS-PAGE gel. The molecular weight (MW) was also confirmed with Voyager DE-Pro MALDI-TOF (Applied Biosystems; Foster City, CA) instrument. The unstructured nature of ZiPPs was confirmed with Circular Dichroism Instrument (Aviv 202). For animal experiments, endotoxin is removed using a Detoxi-Gel (Thermo Scientific; Waltham, MA).

[0098] *In vivo pharmacokinetics (PK) Study.* In this study ZiPPs were compared with uncharged polymers (VPGAG)₁₂₀ and (VPGAG)₁₆₀. The polymers were fluorescently labeled with Alexa 488 in the N-terminus and injected into Balb/c mice using tail vein injection. VPGAG, a biopolymer of similar nature but without any charges, was used as a control to show that any change in the pharmacokinetic parameters seen is the result of the charges incorporated in the VPX₁X₂G motif. Each mouse received a single dose of ZiPPs or control (150 mg/kg BW), injected *i.v or subcutaneously*. Blood samples were collected (10 µL collected into tubes with 100 µL of heparin) at 40 sec, 15 min, 0.5, 2, 4, 8, 24, 48, and 72 hours after injection from the tail vein. The concentration of fluorescently labeled polymer in the blood was calculated using a standard curve of Alexa 488. Blood concentration time-course data was analyzed with a standard two compartment PK model for *i.v.* pk data to ascertain the pharmacokinetic parameters.

[0099] Paclitaxel (PTX) conjugation. Eight periodically spaced cysteine residues arranged in a (VPGXG)₁₆, x is V or C 1:1, motif was cloned to the C-terminus of ZiPP. The drug conjugation segment contained eight cysteines to which multiple copies of PTX were conjugated. First 2'OH of PTX was modified with levulinic acid (Etrych, T.S., et al. *Molecular Pharmaceutics* **2010**, 7, 1015-1026). This modification retains the cytotoxicity of PTX. Activated PTX was then conjugated to free thiols using an acid-labile hydrazide linker (N-ε-Maleimidocaproic acid hydrazide (EMCH) linker) with a terminal maleimide that reacted with thiol groups on ZiPPs to form a stable carbon-sulfur bond (Andrew MacKay, J., et al. *Nat. Mater.* **2009**, 8, 993-999).

[00100] Characterization of ZiPP-PTX drug conjugation. Purity of the drug conjugation was evaluated using High Performance Liquid Chromatography (HPLC). The HPLC data was quantified using the integrated area under the peak at an absorbance of 228 nm that corresponds to the absorbance of PTX. The conjugation ratio of drugs to ZiPPs was determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) a Voyager DE-Pro MALDI-MS (Applied Biosystems; Foster City, CA) instrument equipped with a nitrogen laser (337 nm). Dynamic Light Scattering (DLS) technique was performed to determine the hydrodynamic radius (Rh) of the ZiPP-PTX nanoparticle at 25°C and 25 μM concentration using a Dynapro plate reader (Wyatt Technology; Santa Barbara, CA). The data was analyzed with a regularization fit of the autocorrelation function and the percentage intensity was converted to mass intensity using Raleigh spheres model. Regularization fit was then used to determine the hydrodynamic radius as weighted by the percent by mass for a random coil. Radius of gyration was calculated using Static Light Scattering (SLS) after PTX conjugation. The form factor (ρ) was calculated as Rg/Rh.

[00101] In vitro cytotoxicity of ZiPP-PTX conjugates. *In vitro* cytotoxicity was done on MDA-MB-231 human triple negative breast cancer cells. 3x10³ cells were seeded per 100 μL of media in Falcon™ 96-well cell culture plates (BD; Franklin Lakes, NJ). The cells were allowed to adhere for 16-18 hours before being treated with free PTX and ZiPP-PTX at concentrations that ranged from sub-nanomolar to high-micromolar range. After 72 hours of drug treatment, 20 μL of 3-(4,5,-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent (CellTiter 96 AQueous™ Promega; Madison, WI) was added to each well and incubated for an additional 2 hours. A dose-response curve for free drug and ZiPP-drug conjugate was constructed by measuring the absorbance of each well at 490 nm with a Victor3

microplate reader (Perkin Elmer; Waltham, MA). The 50% inhibitory concentration, IC_{50} , was determined by fitting data to the following equation (Andrew MacKay, J., et al. *Nat. Mater.* **2009**, *8*, 993-999):

$$V_{\%} = 100\% / \left[1 + \left(\frac{C_{\text{treatment}}}{IC_{50}} \right)^p \right]$$

where V is viability of cells, $C_{\text{treatment}}$ is drug concentration, and p is slope of the dose response curve. This IC_{50} value is used to evaluate the potency of the conjugates.

Example 2

Expression and purification of ZiPPs

[00102] The thermally responsive property of ZiPPS enabled a simple non-chromatographic purification using ITC. The appearance of a single band in copper stained SDS-PAGE gel confirmed the purity of the product (**FIG. 2A**). Two different ZiPPs, (VPKEG)₈₀, (MW=44 kDa) and (VPREG)₈₀, (MW=42 kDa) are shown as representatives of purified products in **FIG. 7A**. The 50 kDa ladder is marked as a reference MW in the gel, however the ladder used in SDS gels is from globular proteins and hence is not directly comparable to unstructured ZiPPs. To confirm the purity and MW, we analyzed the purified product by MALDI-TOF. The MALDI spectrum showed the presence of ions at m/z values of 21 kDa and 42 kDa (peaks 1 and 2) for (VPKEG)₈₀ and m/z values of 22 kDa and 44 kDa (peaks 3 and 4) for (VPREG)₈₀ (**FIG. 7B**). The MALDI spectrum showed the presence of ions at m/z values of 20 kDa, 30 kDa, and 60.5 kDa for (VPKDG)₁₂₀ and m/z values of 21 kDa and 32 kDa and 63.8 kDa for (VPRDG)₁₂₀ (**FIG. 2B**), which confirmed the molecular weight of the purified ZiPP constructs (MW=60.5 kDa, MW=63.8 kDa respectively). We also confirmed the intrinsic disordered nature of the ZiPPs by using CD-Spectra. The CD-spectra in **FIG. 2D** and **FIG. 7C** showed negative ellipticity in low wavelength and slightly positive ellipticity in higher wave length, which is characteristic of a random-coil, which is typical of a disordered structure like ELPs and confirmed the unstructured nature of the polymer. Hydrodynamic radius was measured using Dynamic Light Scattering and showed well hydrated ZiPPs compared to ELP controls (**FIG. 2C**). Native PAGE gel showed that ZiPPs do not interact with albumin (**FIG. 2E**).

Example 3

In-vivo pharmacokinetic study

[00103] To determine the pharmacokinetic parameters of ZiPPs, the plasma concentration was tracked over a period of 72 hours following systemic administration in mice via tail vein injection or sub-cutaneous injection. An uncharged polymer with matched amino acid length was used as the control. The experimental design is shown in FIG. 3A and FIG. 4A. The polymers were fluorescently labeled with Alexa488 and injected into mice. Blood samples were collected at various time points up to 72 hours. ELP120 (VPGAG)₁₂₀ was used as a length control while ELP160 (VPGAG)₁₆₀ was used as a molecular weight control. FIG. 3B and FIG. 4B show the plasma polymer concentration as a function of time post-injection, which showed that incorporating a zwitterionic motif (specifically including K, D, and E for X₁ and X₂, respectively) imparted stealth property, which in return increased the circulation time of the polymer compared to uncharged ELPs. Plasma concentrations as a function of time post-injection showed that ZiPPs performed better than ELPs. These polymers followed a two compartmental model and thus the half-life and area under the curve was calculated using this model. A two-compartment model was fitted to the plasma polymer concentration, which yielded pharmacokinetic parameters area under the curve (AUC) (FIG. 3C and FIG. 4C) and elimination half-life (FIG. 3D). AUC was calculated as a measure of the total polymer exposure over the time course of the experiment. The AUC showed that VPKEG and VPKDG performed significantly better than uncharged ELP length controls as well as the molecular weight control. Data represent mean±SE, n=5 for FIG. 3C, and data represent mean±SE, n=3-4 for FIG. 4C. The terminal half-life of ZiPPs increased by 6 hours compared to that of VPGAG constructs (FIG. 3D). Moreover, the most descriptive pharmacokinetic parameter, the total cumulative blood exposure of the polymer, measured by area under the plasma concentration curve (AUC) for ZiPPs was about three times higher than that of the uncharged polypeptide, VPGAG of same chain length (FIG. 3C). The result showed that incorporating a zwitterionic motif and more specifically charged residues into the peptide polymer does play a significant role in improving the pharmacokinetics of the polymer.

Example 4

Characterization of Paclitaxel-ZiPP conjugates

[00104] Paclitaxel (PTX) was chemically conjugated to (VPGXG)₁₆, with X-V or C, in a ratio 1:1, at a trailer at the C-terminus of 120 repeats of the VPKEG pentapeptide unit. Paclitaxel was chemically conjugated to the 8 C-terminal residues via a pH sensitive linker. The design is shown in FIG. 5A. The polymer drug conjugate was purified using Amicon Ultra-15 Centrifugal Filter Units (MWCO: 10kDa; Millipore; Billerica, MA) and the purified product was run on HPLC to confirm the absence of unreacted free drugs. The HPLC chromatogram confirmed the purity of the polymer-drug conjugate with negligible amount of free drugs. Purified ZiPP-PTX conjugate had 3.2-4 drugs per polymer chain as confirmed by the difference in MW calculated between the parent ZiPP polymer chain and ZiPP-PTX conjugate using MALDI-TOF spectra (FIG. 5B). Moreover, Dynamic Light Scattering measurement indicated that after PTX conjugation, ZiPPs indeed spontaneously self-assembled into nanoparticles of hydrodynamic radius (Rh) of 58 nm. They self-assembled into micelles of 58 nm radius with aggregation number of 26 per micelle. The form factor (ρ)—calculated as R_g/R_h —was 0.82, which denotes formation of spherical micelles.

Example 5

In vitro anti-tumor efficacy of ZiPP-PTX conjugates

[00105] The *in vitro* cytotoxicity of ZiPP-PTX was measured by looking at the cell viability over a range of concentrations as a function of time. MDA-MB-231 was used as the model, a human triple negative breast cancer cell line. After 72 hours of drug treatment, the proliferation of MDA-MB-231 cells was inhibited compared to the control (no drug) (FIG. 5C). Moreover, the inhibition was comparable to that of free drug. The IC₅₀ value for free drug was around 2 nM while that of ZiPP-PTX was 12.4 nM (concentration in terms of the drug). The IC₅₀ value for ZiPP-PTX was 6 times higher than that for free drug, but such result is expected in an *in-vitro* environment, where free drugs can easily diffuse in and out of the cells through drug transporters, while PTX from the drug-polymer conjugate only gets released once it is inside of the endosome. This process is slow because the nanoparticles are uptaken via endocytosis and the drug gets released after the nanoparticles travel to the late endosomes where pH is low. This low pH triggers the release of PTX from ZiPP. These results are encouraging as they indicate that the

PTX-polymer conjugate is stable and is potent enough to take to *in-vivo* platform. IC₅₀ values represented the concentration of the drug that reduced cell viability by 50%.

Example 6

ZiPP-Tn3 conjugates

[00106] Multivalent scaffold protein (Tn3) is a superagonist of TNF-related apoptosis-including ligand receptors 2 (TRAIL2) and was picked as the protein to attached to a ZiPP. The design overview of the fusion protein is shown in **FIG. 6A**. Superagonist of TRAIL2 was chosen because activation of TRAILR2 can induce apoptosis in a variety of human cancers, and hence has a potential for cancer therapeutics. (Tn3)₆ represents 6 tandem repeats of the monomer Tn3 unit, which was engineered by MedImmune to bind to TRAIL2 with high affinity. (Tn3)₆ with various lengths of ZiPP was recombinantly expressed in *E. coli*. SDS-PAGE analysis of affinity purified samples are shown in **FIG. 6B**. A cytotoxicity assay against Colo205 (colon cancer cell) showed that the fusion proteins were highly cytotoxic and their potency was comparable to free protein ((Tn3)₆ without ZIPP attached), as shown in **FIG. 6C**. The IC₅₀ values represented the concentration of the drug that reduced cell viability by 50%.

[00107] The foregoing description of the specific aspects will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific aspects, without undue experimentation, without departing from the general concept of the present disclosure. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed aspects, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.

[00108] The breadth and scope of the present disclosure should not be limited by any of the above-described exemplary aspects, but should be defined only in accordance with the following claims and their equivalents.

[00109] All publications, patents, patent applications, and/or other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, and/or other document were individually indicated to be incorporated by reference for all purposes.

[00110] For reasons of completeness, various aspects of the invention are set out in the following numbered clauses:

[00111] Clause 1. A conjugate comprising: (a) a polypeptide comprising one or more charged motifs, each charged motif independently having an amino acid sequence consisting of SEQ ID NO: 1 (VPX₁X₂G), wherein X₁ is a negatively or positively charged amino acid, and wherein X₂ is the other of a negatively or positively charged amino acid; and (b) one or more drug molecules attached to the polypeptide.

[00112] Clause 2. The conjugate of clause 1, wherein the polypeptide comprises a plurality of charged motifs.

[00113] Clause 3. The conjugate of clause 2, wherein the plurality of charged motifs is repeated in tandem.

[00114] Clause 4. The conjugate of clause any one of the preceding clauses, wherein the polypeptide further comprises one or more uncharged motifs, each uncharged motif independently having an amino acid sequence consisting of SEQ ID NO: 3 (VPGXG), wherein X is any amino acid except proline.

[00115] Clause 5. The conjugate of clause 4, wherein the polypeptide comprises a plurality of uncharged motifs.

[00116] Clause 6. The conjugate of clause 5, wherein the plurality of uncharged motifs is repeated in tandem.

[00117] Clause 7. The conjugate of any one of clauses 4-6, wherein one or more uncharged motifs are positioned between at least two adjacent charged motifs of the polypeptide.

[00118] Clause 8. The conjugate of clause 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2 (VPX₁X₂G)_n, wherein X₁ is a negatively or positively charged

amino acid, X_2 is the other of a negatively or positively charged amino acid, and n is an integer greater than or equal to 1.

[00119] Clause 9. The conjugate of clause 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 4 $(VPGXG)_n$, wherein X is any amino acid except proline, and n is an integer greater than or equal to 1.

[00120] Clause 10. The conjugate of clause 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 5 $(VPX_1X_2G)_n(VPGXG)_m$, wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1.

[00121] Clause 11. The conjugate of clause 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 6 $(VPGXG)_m(VPX_1X_2G)_n$, wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1.

[00122] Clause 12. The conjugate of clause 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 7 $\{(VPX_1X_2G)(VPGXG)\}_b$, wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and b is an integer greater than or equal to 1.

[00123] Clause 13. The conjugate of any one of clauses 1-12, wherein X_1 is a negatively charged amino acid, and wherein X_2 is a positively charged amino acid.

[00124] Clause 14. The conjugate of any one of clauses 1-12, wherein X_1 is a positively charged amino acid, and wherein X_2 is a negatively charged amino acid.

[00125] Clause 15. The conjugate of any one of the preceding clauses, wherein the negatively charged amino acid is independently selected from glutamic acid and aspartic acid.

[00126] Clause 16. The conjugate of any one of the preceding clauses, wherein the positively charged amino acid is independently selected from lysine and arginine.

[00127] Clause 17. The conjugate of any one of clauses 4-16, wherein X is any amino acid except proline.

[00128] Clause 18. The conjugate of clause 17, wherein X is selected from arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan.

[00129] Clause 19. The conjugate of clause 18, wherein X is selected from glycine and valine.

[00130] Clause 20. The conjugate of any one of the preceding clauses, wherein the polypeptide further comprises a linker.

[00131] Clause 21. The conjugate of clause 20, wherein the linker comprises one or more cysteines.

[00132] Clause 22. The conjugate of any one of clauses 20-21, wherein the linker comprises an amino acid sequence selected from SEQ ID NO: (GGC), SEQ ID NO: ((GGC)₈), SEQ ID NO: ((G₄S)₃), and SEQ ID NO: ((VPGXG)₁₆ wherein X is valine or cysteine present in a ratio of 1:1).

[00133] Clause 23. The conjugate of any one of clauses 20-22, wherein the linker is positioned at the C-terminus, at the N-terminus, or at both C- and N-termini of the polypeptide.

[00134] Clause 24. The conjugate of any one of clauses 20-23, wherein the one or more drug molecules are attached to the polypeptide via the linker.

[00135] Clause 25. The conjugate of any one of clauses 20-24, wherein the drug molecule is attached to the polypeptide through a thiol reactive group in the linker.

[00136] Clause 26. The conjugate of any one of the preceding clauses, wherein the one or more drug molecules are selected from a small molecule, nucleotide, polynucleotide, peptide, protein, carbohydrate, and a combination thereof.

[00137] Clause 27. The conjugate of clause 26, wherein the drug molecule comprises a small molecule.

- [00138] Clause 28. The conjugate of clause 26, wherein the drug molecule comprises a protein.
- [00139] Clause 29. The conjugate of any one of clauses 1-25, wherein the drug molecule comprises a cancer therapeutic.
- [00140] Clause 30. The conjugate of any one of clauses 1-25, wherein the drug molecule comprises an antibody.
- [00141] Clause 31. The conjugate of any one of clauses 1-25, wherein the drug molecule comprises a paclitaxel.
- [00142] Clause 32. The conjugate of any one of clauses 1-25, wherein the drug molecule comprises Tn3 (TRAIL superagonist).
- [00143] Clause 33. The conjugate of any one of the preceding clauses, wherein the conjugate is prepared for administration to a subject.
- [00144] Clause 34. The conjugate of any one of the preceding clauses, wherein the polypeptide of the conjugate is recombinantly expressed.
- [00145] Clause 35. The conjugate of clause 28, wherein the conjugate is recombinantly expressed.
- [00146] Clause 36. A composition comprising the conjugate of any one of the preceding clauses.
- [00147] Clause 37. A polynucleotide encoding the polypeptide of any one of clauses 1-35.
- [00148] Clause 38. A polynucleotide encoding the conjugate of clause 28.
- [00149] Clause 39. A vector comprising the polynucleotide of clause 37 or 38.
- [00150] Clause 40. A method of delivering a drug molecule to a subject, the method comprising administering the conjugate of any one of clauses 1-35 to the subject.
- [00151] Clause 41. A method of treating a subject having a disease or disorder, the method comprising administering the conjugate of any one of clauses 1-35 to the subject.

[00152] Clause 42. A method of determining the presence of a target in a sample, the method comprising: contacting the sample with the conjugate of any one of clauses 1-35 under conditions to allow a complex to form between the drug molecule and the target in the sample; and detecting the presence of the complex, wherein presence of the complex is indicative of the target in the sample.

[00153] Clause 43. The method of clause 42, wherein the sample is obtained from a subject and the method further comprises diagnosing a disease, prognosticating, or assessing the efficacy of a treatment of the subject.

[00154] Clause 44. The method of clause 43, wherein when the method further comprises assessing the efficacy of a treatment of the subject, then the method further comprises modifying the treatment of the subject as needed to improve efficacy.

[00155] Clause 45. A method of diagnosing a disease in a subject, the method comprising: contacting a sample from the subject with the conjugate of any one of clauses 1-35 under conditions to allow a complex to form between the drug molecule and a target in the sample; determining the level of the target in the sample, wherein level of the complex is indicative of the level of the target in the sample; and comparing the level of the target in the sample to a control level of the target, wherein a level of the target different from the control level indicates disease in the subject.

[00156] Clause 46. The method of clause 45, wherein the control level corresponds to the level in the subject at a time point before or during the period when the subject has begun treatment, and wherein the sample is taken from the subject at a later time point.

[00157] Clause 47. The method of clause 45, wherein the sample is taken from the subject at a time point during the period when the subject is undergoing treatment, and wherein the control level corresponds to a disease-free level or to the level at a time point before the period when the subject has begun treatment.

[00158] Clause 48. The method of any one of clauses 45-47, the method further comprising modifying the treatment or administering a different treatment to the subject when the treatment is determined to be ineffective in treating the disease.

[00159] Clause 49. The method of any one of clauses 40-48, wherein the conjugate is labeled with a reporter.

[00160] Clause 50. The method of any one of clauses 40-49, wherein the conjugate is administered to the subject intravenously, intraarterially, intraperitoneally, or intratumorally.

[00161] Clause 51. The method of any one of clauses 40-50, wherein the conjugate has reduced antigenicity relative to the drug molecule conjugated to polyethylene glycol (PEG).

[00162] Clause 52. The method of any one of clauses 40-50, wherein the conjugate has reduced immunogenicity relative to the drug molecule conjugated to polyethylene glycol (PEG).

[00163] Clause 53. The method of any one of clauses 40-52, wherein the disease is selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorder.

[00164] Clause 54. The method of clause 53, wherein the disease comprises cancer.

[00165] Clause 55. The method of clause 54, wherein the cancer is selected from breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer.

[00166] Clause 56. The method of clause 55, wherein the cancer comprises breast cancer.

SEQUENCES

SEQ ID NO: 1

VPX₁X₂G, wherein X₁ is a negatively or positively charged amino acid, and wherein X₂ is the other of a negatively or positively charged amino acid.

SEQ ID NO: 2

(VPX₁X₂G)_n, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, and n is an integer greater than or equal to 1.

SEQ ID NO: 3

VPGXG, wherein X is any amino acid except proline.

SEQ ID NO: 4

$(VPGXG)_n$, wherein X is any amino acid except proline, and n is an integer greater than or equal to 1.

SEQ ID NO: 5

$(VPX_1X_2G)_n(VPGXG)_m$, wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1.

SEQ ID NO: 6

$(VPGXG)_m(VPX_1X_2G)_n$, wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1.

SEQ ID NO: 7

$\{(VPX_1X_2G)(VPGXG)\}_b$, wherein X_1 is a negatively or positively charged amino acid, X_2 is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and b is an integer greater than or equal to 1.

SEQ ID NO: 8

GGC

SEQ ID NO: 9

$(GGC)_8$

SEQ ID NO: 10

$(G_4S)_3$

SEQ ID NO: 11

$(VPGXG)_{16}$ wherein X is valine or cysteine present in a ratio of 1:1.

SEQ ID NO: 12

Example polypeptide

VPKDGVPKDGVPKDGVPKDGVPKDG

SEQ ID NO: 13

Polynucleotide encoding example polypeptide

GTC CCG aaa gac GGT GTT CCG aag gac GGC GTG CCT aaa gat GGT GTT CCG aag gac

GGG GTG CCA aaa gat GGG

CLAIMS

We claim:

1. A conjugate comprising:
 - (a) a polypeptide comprising one or more charged motifs, each charged motif independently having an amino acid sequence consisting of SEQ ID NO: 1 (VPX₁X₂G), wherein X₁ is a negatively or positively charged amino acid, and wherein X₂ is the other of a negatively or positively charged amino acid; and
 - (b) one or more drug molecules attached to the polypeptide.
2. The conjugate of claim 1, wherein the polypeptide comprises a plurality of charged motifs.
3. The conjugate of claim 2, wherein the plurality of charged motifs is repeated in tandem.
4. The conjugate of any one of the preceding claims, wherein the polypeptide further comprises one or more uncharged motifs, each uncharged motif independently having an amino acid sequence consisting of SEQ ID NO: 3 (VPGXG), wherein X is any amino acid except proline.
5. The conjugate of claim 4, wherein the polypeptide comprises a plurality of uncharged motifs.
6. The conjugate of claim 5, wherein the plurality of uncharged motifs is repeated in tandem.
7. The conjugate of any one of claims 4-6, wherein one or more uncharged motifs are positioned between at least two adjacent charged motifs of the polypeptide.
8. The conjugate of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2 (VPX₁X₂G)_n, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, and n is an integer greater than or equal to 1.

9. The conjugate of claim 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 4 (VPGXG)_n, wherein X is any amino acid except proline, and n is an integer greater than or equal to 1.
10. The conjugate of claim 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 5 (VPX₁X₂G)_n(VPGXG)_m, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1.
11. The conjugate of claim 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 6 (VPGXG)_m(VPX₁X₂G)_n, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and n and m are independently an integer greater than or equal to 1.
12. The conjugate of claim 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 7 {(VPX₁X₂G)(VPGXG)}_b, wherein X₁ is a negatively or positively charged amino acid, X₂ is the other of a negatively or positively charged amino acid, X is any amino acid except proline, and b is an integer greater than or equal to 1.
13. The conjugate of any one of claims 1-12, wherein X₁ is a negatively charged amino acid, and wherein X₂ is a positively charged amino acid.
14. The conjugate of any one of claims 1-12, wherein X₁ is a positively charged amino acid, and wherein X₂ is a negatively charged amino acid.
15. The conjugate of any one of the preceding claims, wherein the negatively charged amino acid is independently selected from glutamic acid and aspartic acid.
16. The conjugate of any one of the preceding claims, wherein the positively charged amino acid is independently selected from lysine and arginine.

17. The conjugate of any one of claims 4-16, wherein X is any amino acid except proline.
18. The conjugate of claim 17, wherein X is selected from arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan.
19. The conjugate of claim 18, wherein X is selected from glycine and valine.
20. The conjugate of any one of the preceding claims, wherein the polypeptide further comprises a linker.
21. The conjugate of claim 20, wherein the linker comprises one or more cysteines.
22. The conjugate of any one of claims 20-21, wherein the linker comprises an amino acid sequence selected from SEQ ID NO: (GGC), SEQ ID NO: ((GGC)₃), SEQ ID NO: ((G₄S)₃), and SEQ ID NO: ((VPGXG)₁₆ wherein X is valine or cysteine present in a ratio of 1:1).
23. The conjugate of any one of claims 20-22, wherein the linker is positioned at the C-terminus, at the N-terminus, or at both C- and N-termini of the polypeptide.
24. The conjugate of any one of claims 20-23, wherein the one or more drug molecules are attached to the polypeptide via the linker.
25. The conjugate of any one of claims 20-24, wherein the drug molecule is attached to the polypeptide through a thiol reactive group in the linker.
26. The conjugate of any one of the preceding claims, wherein the one or more drug molecules are selected from a small molecule, nucleotide, polynucleotide, peptide, protein, carbohydrate, and a combination thereof.
27. The conjugate of claim 26, wherein the drug molecule comprises a small molecule.
28. The conjugate of claim 26, wherein the drug molecule comprises a protein.

29. The conjugate of any one of claims 1-25, wherein the drug molecule comprises a cancer therapeutic.
30. The conjugate of any one of claims 1-25, wherein the drug molecule comprises an antibody.
31. The conjugate of any one of claims 1-25, wherein the drug molecule comprises a paclitaxel.
32. The conjugate of any one of claims 1-25, wherein the drug molecule comprises Tn3 (TRAIL superagonist).
33. The conjugate of any one of the preceding claims, wherein the conjugate is prepared for administration to a subject.
34. The conjugate of any one of the preceding claims, wherein the polypeptide of the conjugate is recombinantly expressed.
35. The conjugate of claim 28, wherein the conjugate is recombinantly expressed.
36. A composition comprising the conjugate of any one of the preceding claims.
37. A polynucleotide encoding the polypeptide of any one of claims 1-35.
38. A polynucleotide encoding the conjugate of claim 28.
39. A vector comprising the polynucleotide of claim 37 or 38.
40. A method of delivering a drug molecule to a subject, the method comprising administering the conjugate of any one of claims 1-35 to the subject.
41. A method of treating a subject having a disease or disorder, the method comprising administering the conjugate of any one of claims 1-35 to the subject.

42. A method of determining the presence of a target in a sample, the method comprising:
contacting the sample with the conjugate of any one of claims 1-35 under conditions to allow a complex to form between the drug molecule and the target in the sample; and
detecting the presence of the complex, wherein presence of the complex is indicative of the target in the sample.

43. The method of claim 42, wherein the sample is obtained from a subject and the method further comprises diagnosing a disease, prognosticating, or assessing the efficacy of a treatment of the subject.

44. The method of claim 43, wherein when the method further comprises assessing the efficacy of a treatment of the subject, then the method further comprises modifying the treatment of the subject as needed to improve efficacy.

45. A method of diagnosing a disease in a subject, the method comprising:
contacting a sample from the subject with the conjugate of any one of claims 1-35 under conditions to allow a complex to form between the drug molecule and a target in the sample;
determining the level of the target in the sample, wherein level of the complex is indicative of the level of the target in the sample; and
comparing the level of the target in the sample to a control level of the target, wherein a level of the target different from the control level indicates disease in the subject.

46. The method of claim 45, wherein the control level corresponds to the level in the subject at a time point before or during the period when the subject has begun treatment, and wherein the sample is taken from the subject at a later time point.

47. The method of claim 45, wherein the sample is taken from the subject at a time point during the period when the subject is undergoing treatment, and wherein the control level corresponds to a disease-free level or to the level at a time point before the period when the subject has begun treatment.

48. The method of any one of claims 45-47, the method further comprising modifying the treatment or administering a different treatment to the subject when the treatment is determined to be ineffective in treating the disease.

49. The method of any one of claims 40-48, wherein the conjugate is labeled with a reporter.
50. The method of any one of claims 40-49, wherein the conjugate is administered to the subject intravenously, intraarterially, intraperitoneally, or intratumorally.
51. The method of any one of claims 40-50, wherein the conjugate has reduced antigenicity relative to the drug molecule conjugated to polyethylene glycol (PEG).
52. The method of any one of claims 40-50, wherein the conjugate has reduced immunogenicity relative to the drug molecule conjugated to polyethylene glycol (PEG).
53. The method of any one of claims 40-52, wherein the disease is selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorder.
54. The method of claim 53, wherein the disease comprises cancer.
55. The method of claim 54, wherein the cancer is selected from breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer.
56. The method of claim 55, wherein the cancer comprises breast cancer.

FIGURES

Homopolymer $(VP\bar{X}_1\bar{X}_2G)_n$




FIG. 1A

Diblock $(VP\bar{X}_1\bar{X}_2G)_n(VPGXG)_n$




FIG. 1B

Multiblock $(VP\bar{X}_1\bar{X}_2G)_n(VPGXG)_n$




FIG. 1C

Possible Sequences $(VPX_1X_2G)_n$	
<i>VPKEG</i>	<i>VPKDG</i>
<i>VPREG</i>	<i>VPRDG</i>

FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C






FIG. 2D



ABP-Albumin Binding Peptide

FIG. 2E



I.V. PK Study

➤ Experimental Design:

- VPGAG-120 (no of repeats control)] ELP
- VPGAG-160 (MW control)]
- VPKEG-120 |
- VPREG-120 | ZIPP
- VPKDG-120 |
- VPRDG-120 |

FIG. 3A






FIG. 3B



*length control is same as number of repeats control



AUC [nM hr]	VPAG 120	VPREG 120	VPKDG 120	VPKDG 120	VPKDG 120	VPKDG 120
Mean	49.5	64.2	130.6	73.3	147.7	51.2
SD	9.9	9.4	8.4	4.9	8.7	5.2

FIG. 3C





FIG. 3D



➤ **Experimental Design:**

- VPGAG-120 (no of repeats control)
- VPGAG-160 (MW control)
- VPKEG-120
- VPKDG-120

FIG. 4A






FIG. 4B



*length control is same as number of repeats control



-VPKEG vs VPKDG ns at 0.05

- VPGAG-120
- ▨ VPGAG-160
- ▩ VPKEG-120
- ▧ VPKDG-120

250000

200000

150000

100000

50000

0

FIG. 4C




FIG. 5A

ZIPP ₁₂₀	-PTX	+PTX				
	Rh (nm)	Rh (nm)	Rg (nm)	ρ	Nagg	CMC (μ M)
	7	58	47.6	0.82	26	4

Drug Conjugation by MALDI





FIG. 5B



	Free PTX		CP-PTX		ZIPP-PTX
	[Drug]	[Polymer]	[Drug]	[Polymer]	[Drug]
IC 50 [nM]	2	4.6	9.2	3.1	12.4

FIG. 5C




FIG. 6A





FIG. 6B



	(Tn3) ₆ (Free)	(Tn3) ₆ -ZIPP ₁₂₀
IC50 [pM]	1.5	22.2

FIG. 6C




FIG. 7B




FIG. 7A




FIG. 7C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US16/45655

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 39/00, 39/395, 47/48 (2016.01)

CPC - A61K 39/00, 39/395, 47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 39/00, 39/395, 47/00, 47/48 (2016.01)

CPC: A61K 39/00, 39/395, 47/00, 47/48; C07K 2319/01

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, INPADOC Data); EBSCO Discovery; PubMed; Google; Google Scholar; Google Patents; The Lens; ENA; NCBI Blast; KEYWORDS: conjugate, polypeptide, charge, motif, drug

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011/123813 A2 (AMUNIX OPERATING INC.) October 6, 2011; abstract; paragraph [00158]	1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 8, 9/4/1-3, 10/4/1-3, 11/4/1-3, 12/4/1-3
A	US 2011/0119778 A1 (LISS, M) May 19, 2011; paragraph [0053]	1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 8, 9/4/1-3, 10/4/1-3, 11/4/1-3, 12/4/1-3
A	US 2013/0330335 A1 (BREMEL, R et al.) December 12, 2013; paragraph [0043]	1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 8, 9/4/1-3, 10/4/1-3, 11/4/1-3, 12/4/1-3

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"E" earlier application or patent but published on or after the international filing date

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"&" document member of the same patent family

Date of the actual completion of the international search

01 November 2016 (01.11.2016)

Date of mailing of the international search report

02 DEC 2016

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/45655

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.: 7, 13-56
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.